dometrial stromal nodules (ESN), HG-ESS, and UUS. ESS are staged along with uterine leiomyosarcomas in accordance with the FIGO and TNM classifications ( table 1 ) [2, 10] .
Tumor stage is the most important prognostic factor in LG-ESS [11] , followed by the patient's age. Another unfavorable factor that has been discussed is uterine morcellation [12] [13] [14] . The relevance of mitotic rate, evidence of p53, and tumor necrosis is unclear [7, 11, 15, 16] .
In addition to arising in the uterus, LG-ESS can also develop in extrauterine locations such as the ovaries, the pelvis, or the abdominal cavity, and also the vagina or vulva [17] . Endometriosis is found in 50% of these cases, giving rise to the suspicion that stromal sarcomas can develop out of endometriosis [18] .
Approximately 65% of the patients are FIGO stage I-II at the time of diagnosis, and around 35% have FIGO stage III-IV [19] . In patients with tumor stage I-II, the 5-year survival rate is over 90%, while with stages III-IV it is around 50%.
Classification of Endometrial Stromal Tumors
The classification of endometrial stromal tumors has been extremely difficult for many decades. These tumors were initially differentiated mainly on the basis of mitoses per 10 high-powered fields (HPF). A mitotic index of < 10/10 HPF was associated with a 100% 5-year survival rate, whereas with a mitotic index of > 10/10 HPF the figure was only 55% [20] . However, it has been known since as early as 1982 that the number of mitoses does not correlate with prognostic validity, making it unsatisfactory and impracticable as a distinguishing criterion. This type of classification is therefore regarded in the literature as obsolete [18, 21] . In 1990, Chang et al. [22] drew a distinction between ESS grade 1, 2, or 3 and undifferentiated sarcomas. Kurihara et al. [23] proposed a distinction between LG-ESS, undifferentiated endometrial sarcomas with nuclear uniformity (UES-U), and undifferentiated endometrial sarcomas with nuclear pleomorphism (UES-P). In 2012, Lee et al. [24] [25] [26] [27] achieved a breakthrough by demonstrating a genomic rearrangement that led to a fusion of YWHAE and FAM22A/B through a translocation of chromosomes 10 and 17 (t(10; 17) ). This 14-3-3 oncoprotein appears to be highly specific for HG-ESS. It was hoped that this genetic feature would make it possible to distinguish between LG-ESS and HG-ESS. The WHO, having in the meantime abandoned the term 'high-grade stromal sarcoma', thus reintroduced the category of HG-ESS in the 2014 classification. Currently, a distinction is now made between LG-ESS, HG-ESS, and UUS. ESS and UUS are distinguished on the basis of morphologic, immunohistochemical, and molecular-pathologic criteria [4] .
Pathology
The cut surface of LG-ESS is yellowish to yellowish-brown, and may also be partly pinkish [18] .
LG-ESS can grow intramurally or submucosally, with unclear margins relative to the surrounding tissue [27] . Polypoid growth may lead to displacement of the uterine cavity when the findings are extensive [18] .
As malignant tumors, LG-ESS arise from mesenchymal cells that resemble the endometrial stroma in the proliferation phase [2] . Evidence of intratumoral hemorrhage and/or necrosis varies. Typical findings consist of numerous small, uniform cells with linguiform infiltration into the myometrium and into blood and lymph vessels [18, 27] . The number of mitoses varies but is usually in the low range (< 5/10 HPF), although larger numbers do not exclude the diagnosis [18, 27] . It may be difficult to distinguish between LG-ESS with focal glandular differentiation on the one hand and endometriosis on the other [28] . They can be distinguished from ESN by examining their mitotic activity, which is usually lower in ESN [4, 29] . Infiltration of the myometrium is not observed with ESN, but finger-like projections into the neighboring myometrium are accepted if there are fewer than 3 and they are smaller than 3 mm [27] .
Additional immunohistochemical examinations and molecularpathologic analyses may make it easier to establish a diagnosis. Majority expression of CD10 and WT1 has been reported [4, 30] . Reich et al. [31] noted high levels of expression of estrogen and progesterone receptors in 71 and 95% of cases, respectively. Most ESS express aromatases [32] . Their expression is associated with tumor growth and may also be relevant to the high recurrence rate [32] . The tumors also sometimes express gonadotrophin-releasing hormone (GnRH) receptors [18] . One therapeutic approach that may be considered is therefore treatment with gestagens, aromatase inhibitors, and GnRH analogues. Around 45% of the tumors express androgen receptors [33] . Evidence of smooth-muscle actin, β-catenin, and pancytokeratins is also possible, whereas CD117 is negative [4] . Cyclin D1 shows variable and heterogeneous nuclear expression in < 10% of the tumor cells and may be important for distinguishing between these lesions and HG-ESS [1, 4] .
LG-ESS are a group of lesions with heterogeneous molecularpathologic findings, but several genetic changes observed in them are important, such as the translocation t(7; 17)(p15;q21) with fusion of JAZFI-SUZ12 and the fusion genes JAZF1-PHF1 and more rarely EPC1-PHF1 , MEAF6-PHF1 , ZC3H7-BCOR , and MBTDCXorf67 [27] . A p53 mutation may be found in about one-quarter of ESS; research has shown that changes in p53 may play an important role in the carcinogenesis in these tumors, although they have no influence on prognosis [34] .
Clinical Presentation
ESS typically develop in premenopausal and perimenopausal women with a mean age of 46 (range 18-83 years) [22] . Rare cases have been reported of the tumor developing in connection with tamoxifen or estrogen administration, as well as after radiotherapy [35, 36] . Obesity, diabetes mellitus, and early menarche are reported to be associated with an increased risk of LG-ESS [17] .
These tumors often become apparent through pathologic vaginal bleeding, sometimes also combined with uterine enlargement and associated symptoms such as lower abdominal pain [2, 22] .
Diagnosis
In contrast to carcinomas of the endometrium, a diagnosis of LG-ESS as a mesenchymal tumor cannot be securely established using hysteroscopy and fractional curettage. In addition, a clear distinction from benign ESN can only be reliably made after histological analysis of the tumor's entire interface with the neighboring myometrium [17] . Imaging procedures such as ultrasound, computed tomography, and magnetic resonance imaging are not able to display any specific characteristics of LG-ESS [37] .
Surgical Treatment
The primary treatment for LG-ESS is surgery with total hysterectomy (without morcellation) and bilateral salpingo-oophorectomy [4] . Cytoreduction is recommended in advanced tumors with extrauterine manifestations [38, 39] . However, Leath et al. [40] do not regard this as offering any survival advantage in patients with LG-ESS, and in these cases the extent of surgery has to be decided on an individual basis, depending on symptoms and with palliative intent.
It has been shown that LG-ESS are hormone-dependent [12] . It is not clear whether the ovaries can be preserved in young, premenopausal women. Several studies have found a significantly increased rate of recurrence when the ovaries were preserved in premenopausal women [41] [42] [43] . In addition, LG-ESS have high levels of steroid receptors and metastasize most frequently from the uterus to the ovaries. A Surveillance Epidemiology and End Results (SEER) analysis did not show any negative effects on overall survival when the ovaries were preserved in premenopausal patients [44] . The decision whether or not to preserve the ovaries therefore always needs to be critically discussed with the patient, with the potential advantage of preserving the ovaries being carefully weighed against the increased risk of recurrence. In view of the tumor biology of LG-ESS, estrogen therapy after bilateral oophorectomy cannot be recommended [45] .
Involvement of the pelvic and para-aortic lymph nodes does not appear to have any influence on prognosis. In the study by Chan et al. [19] , lymphadenectomy was not associated with any significant improvement in survival, but almost 10% of the patients who underwent lymphadenectomy had lymph node metastases. Other authors have taken the view that lymphadenectomy may potentially reduce the number of recurrences in the pelvis [46, 47] , but intraabdominal spread and distant metastases predominate over isolated pelvic recurrences [18] . The SEER data also did not show any benefit of lymphadenectomy in relation to overall survival [44] . Pelvic and para-aortic lymphadenectomy is therefore not a recommended standard procedure in patients with LG-ESS.
Adjuvant Systemic Therapy
The expression of steroid receptors and aromatases in LG-ESS suggests that adjuvant therapy with gestagens, GnRH analogues, or aromatase inhibitors should be effective. However, a benefit with these endocrine treatments has not been confirmed beyond doubt [45, 46, 48] . In general, the data is limited to case series with small numbers of patients. The heterogeneous distribution pattern of the tumors and potential interaction with androgen receptors are thought to be responsible for the absence of response to gestagen and GnRH analogues, in spite of positive estrogen and progesterone receptors [33] . Gadducci et al. [39] argue in favor of a 24-month course of adjuvant gestagen therapy with megestrol. Adjuvant therapy with aromatase inhibitors for 5 years is recommended by some authors [48] . The role of oophorectomy as an adjuvant ablative form of hormonal therapy remains unclear. For tumors that are not removed with healthy margins, adjuvant endocrine therapy is possibly indicated [39, 49, 50] . The response rates are very high, at 82%, and remission periods of more than 10 years have been reported several times [49] . In another study, the efficacy of aromatase inhibitors and gestagens was compared in the adjuvant hormonal treatment of LG-ESS. In patients who were in stage I, gestagen therapy led to a recurrence-free survival (RFS) of 306.2 months (95% confidence interval (CI) 259.7-352.6 months) compared to 153.1 months (95% CI 56.8-124.9 months) with aromatase inhibitor therapy and 90.8 months (95% CI 56.8-124.9 months) without adjuvant endocrine therapy. However, due to severe side effects such as hot flushes, depression, weight gain, and water retention, gestagen treatment was prematurely stopped much more frequently [51] .
Starting from FIGO stage III, adjuvant endocrine therapy in accordance with today's standard may be considered but should not be carried out as a general rule [4] . Medroxyprogesterone acetate or megestrol acetate or the aromatase inhibitors letrozole, anastrozole, or exemestane may be used [4] .
There are no valid data to show that adjuvant chemotherapy leads to any improvement in survival in patients with LG-ESS. In a Thiel/Halmen Oncol Res Treat 2018;41:687-692 DOI: 10.1159/000494225 690 large observational study conducted by the National Cancer Database, patients with FIGO I ESS received adjuvant chemotherapy. Among 2,414 patients with LG-ESS, 115 (4.8%) received chemotherapy. A total of 444 (33.4%) of 1,383 patients with HG-ESS also received adjuvant chemotherapy, and as many as 75.9% of them (337/444) received multi-agent chemotherapy. A longer survival period was only observed in association with chemotherapy in the group of patients with HG-ESS [52] .
Adjuvant Radiotherapy
In a large epidemiological study conducted in the United States including 3,650 patients with uterine sarcomas, a significant benefit of adjuvant radiotherapy to the pelvis (with or without brachytherapy) was observed in relation to locoregional RFS. The benefit was seen not only for the overall group, but also for the subgroup of patients with ESS (n = 312), with a 5-year locoregional RFS of 97 versus 93% and an 8-year locoregional RFS of 97 versus 87% [53] . However, another large study including 1,010 patients with ESS did not find that adjuvant pelvic radiotherapy had any positive effect on overall survival [54] . A randomized phase III study including a total of 224 patients with uterine sarcomas also included 28 patients with ESS. The patients were randomly assigned to an arm that received postoperative adjuvant pelvic radiotherapy (51 Gy in 28 fractions over 5 weeks), in comparison with observation alone [55] . Although there was a reduction in the local recurrence rate (n = 14 vs. 24; p = 0.004), no effect on progression-free survival or overall survival was seen. The study did not conduct a subgroup analysis of patients with ESS.
Postoperative radiotherapy in patients with ESS thus only appears to improve locoregional control, so that the medium-term and long-term side effects of pelvic irradiation need to be weighed carefully against what is in any case a good prognosis in relation to locoregional recurrences [4] .
Recurrences and Distant Metastases
The risk of recurrence in LG-ESS is 10-20%, and late recurrences after more than 10-30 years are characteristic of the disease [25, 26] . Recurrences may appear locally in the vagina or lesser pelvis, or as distant metastases in the abdominal wall or lung [56] . Only 40% of recurrences are limited exclusively to the lesser pelvis; 60% of them occur intra-abdominally, as distant metastases, or as a combination of all forms of dissemination [57] . The median period to the appearance of recurrences is 5.4-9.3 years in stages I and II and only 9 months in stages III and IV (FIGO prior to 2009) [57, 58] . Distant metastases and recurrences do not show any association with positive lymph nodes. Even in patients with negative lymph node status, recurrence rates of up to 30% within 2 years are observed [59] .
Surgery, radiotherapy, and systemic therapy are regarded as potential treatment options in patients with recurrences of and metastases from uterine sarcomas [60] , but only complete surgical resection is associated with an increased rate of cure and prolonged survival [61] [62] [63] [64] . After each recurrence or isolated metastasis, the extent to which complete resection is possible should therefore be checked. Due to the slow growth of the lesions, ESS can also be repeatedly successfully resected [37] .
Percutaneous radiotherapy can be used for palliative treatment in patients with local or locoregional recurrences of uterine sarcomas [65, 66] . However, even in combination with chemotherapy, tumor progression occurs in more than 50% of the patients within 2 years [65] [66] [67] . Intraoperative radiotherapy or percutaneous irradiation can achieve a 3-year survival rate of 53% and a median survival period of 18 months after surgical treatment in patients with residual tumors [54] .
Due to the high level of expression of estrogen and progesterone receptors in LG-ESS, gestagens or aromatase inhibitors can be administered in patients with postoperative residual tumor, inoperable recurrences, or distant metastases [49, [68] [69] [70] .
Chemotherapy should only be used when other options have been exhausted. There are no studies showing any superiority of combination therapy over monotherapy. The data available are based only on case reports and phase II studies in which other types of uterine sarcoma were also treated [71] .
Due to the expression of epidermal growth factor receptor in 70% of ESS, treatment with monoclonal antibodies or tyrosine kinase inhibitors is conceivable [18, 72] . There have been individual observations of complete remission during treatment with imatinib [73] .
Conclusion
Like the other uterine sarcomas, LG-ESS are a very rare tumor entity. The various diseases used to therefore be combined together in past research studies. In addition, the classification of endometrial stromal tumors presented difficulties for a considerable period so that earlier studies were not always able to distinguish precisely between LG-ESS, HG-ESS, and UUS. For LG-ESS, surgery with hysterectomy and adnexectomy is the first-line treatment. The benefits of lymphadenectomy or tumor debulking are unclear. Endocrine therapies with gestagens and aromatase inhibitors are under discussion as adjuvant treatments in patients with advanced stages. Since it only provides locoregional control in patients who usually have a good prognosis with LG-ESS, radiotherapy needs to be carefully weighed up in relation to its side effects. Repeat surgery is also the treatment of choice in cases of recurrence.
In order to improve the treatment options available for LG-ESS, further research studies need to be conducted in which LG-ESS is considered as a distinct entity.
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